SarinaAnnePiha-PaulMD

Oncology • Houston, TX

Associate Professor, Phase I Fellowship Program Director

Join to view full profile

Dr. Piha-Paul is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Piha-Paul's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-563-1055
Is this information wrong?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Baylor College of MedicineResidency, Internal Medicine, 2002 - 2006
Louisiana State University School of Medicine in New OrleansClass of 2002

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2008 - 2025
OK State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology

Clinical Trials

Bevacizumab and Temsirolimus in Patients With Advanced Malignancy Start of enrollment: 2008 Jan 25
Completed
Phase 1
FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies Start of enrollment: 2009 Apr 09
Completed
Phase 1
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib Start of enrollment: 2010 Jun 01
Completed
Phase 1
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Start of enrollment: 2012 Mar 16
Active, not recruiting
Phase 1
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
LDE225 for Patients With PTCH1 or SMO Mutated Tumors Start of enrollment: 2014 Feb 01
Terminated
Phase 2
BGJ398 for Patients With Tumors With FGFR Genetic Alterations Start of enrollment: 2014 Jul 24
Terminated
Phase 2
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Start of enrollment: 2017 Oct 31
Active, not recruiting
Phase 1
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors Start of enrollment: 2018 Aug 21
Completed
Phase 1
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer Start of enrollment: 2019 Jan 08
Active, not recruiting
Phase 1
Study of AMV564 in Subjects With Advanced Solid Tumors Start of enrollment: 2019 Oct 09
Active, not recruiting
Phase 1
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer Start of enrollment: 2020 Jan 16
Completed
Phase 1
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors Start of enrollment: 2020 Jun 16
Active, not recruiting
Phase 1
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors Start of enrollment: 2020 Jul 07
Recruiting
Phase 1
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Start of enrollment: 2018 Jul 10
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
A Study of EP0031 in Patients With Advanced RET-altered Malignancies Start of enrollment: 2022 Sep 30
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Conley, A. P., Sarina A Piha-Paul, Binghe Xu, Ecaterina E Dumbrava, Siqing Fu, Daniel D Karp, Funda Meric-Bernstam, David S Hong, Jordi A Rodon, Apostolia M Tsimberido...> ;The Oncologist. 2024 Apr 4
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
Jason Roszik, Carmelia Maria Noia Barretto, Erick Campbell, Amber M Johnson, Isabella C Glitza Oliva, Blessie Elizabeth Nelson, Jibran Ahmed, Mirella Nardo, Sarina A P...> ;Molecular Cancer. 2024 Mar 26
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Gerald Falchook, Amita Patnaik, Debra L Richardson, R Donald Harvey, Manish R Sharma, Navid Hafez, Erika Hamilton, Sarina A Piha-Paul, Minal Barve, Trisha Wise-Draper,...> ;Clinical Therapeutics. 2024 Mar 1
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid M...
Subbiah, V., Coleman, N., Piha-Paul, S., Tsimberidou, A., Janku, F., Rodon, J., Pant, S., Dumbrava, E., Fu, S., Hong, D., Zhang, S., Sun, M., Jiang, Y., Roszik, J., So...> ;Cancer Research Communications. 2024 Feb 12
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Coleman, N., Stephen, B., Ahnert, J., Wright, J., Fessahaye, S., Ouyang, F., Yilmaz, B., Fu, S., Karp, D., Subbiah, V., Piha-Paul, S., Meric-Bernstam, F., Naing, A.> ;Cancer Medicine. 2024 Feb 1
1 citations
Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
Jia Luo, Michelle Sanchez, Elinton Lee, Hans Hertzler, Nhi Luong, Emanuele Mazzola, Bryanna Finstein, Rubii Tamen, Gifty Brisbane, Tom Nguyen, Paul K Paik, Jamie E Cha...> ;Journal of Thoracic Oncology. 2024 May 1
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Anne Knisely, Jibran Ahmed, Bettzy Stephen, Sarina A Piha-Paul, Daniel Karp, Abdulrazzak Zarifa, Siqing Fu, David Sanghyun Hong, Jordi Rodon Ahnert, Timothy A Yap, Apo...> ;Cancer. 2024 Feb 1
Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation.
Anca Chelariu-Raicu, Sarina A Piha-Paul, Mariana Chavez-MacGregor, Jason Johnson, Raymond Sawaya, Mary Frances McAleer, Alissa Nguyen, Audrey Hartnett, Apostolia M Tsi...> ;Journal of Immunotherapy and Precision Oncology. 2023 Aug 1
2 citations
Discordance of HER2 Expression and/or Amplification on Repeat Testing.
Timothy P DiPeri, Kathleen Kong, Kaushik Varadarajan, Daniel D Karp, Jaffer A Ajani, Shubham Pant, Michael F Press, Sarina A Piha-Paul, Ecaterina E Dumbrava, Funda Mer...> ;Molecular Cancer Therapeutics. 2023 Aug 1
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 ...
Sarina A Piha-Paul, Chieh Tseng, Hai T Tran, Meng Gao, Daniel D Karp, Vivek Subbiah, Apostolia Maria Tsimberidou, Jitesh D Kawedia, Siqing Fu, Shubham Pant, Timothy A ...> ;Cancer Chemotherapy and Pharmacology. 2023 Aug 1
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
Blessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, Siqing Fu, Vivek Subbiah, Anil K Sood, Jordi Rodon, Daniel D Karp, George Blumenschein, Scott Kopetz, Shu...> ;The Oncologist. 2023 Dec 11
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.
Jason J Luke, Sarina A Piha-Paul, Theresa Medina, Claire F Verschraegen, Mary Varterasian, Aoife M Brennan, Richard J Riese, Anna Sokolovska, James Strauss, David L Ha...> ;Clinical Cancer Research. 2023 Jul 5
Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies.
Jason J Luke, Sarina A Piha-Paul, Theresa Medina, Claire F Verschraegen, Mary Varterasian, Aoife M Brennan, Richard J Riese, Anna Sokolovska, James F Strauss, David L ...> ;Clinical Cancer Research. 2023 May 9
3 citations
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).
Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, Shiraj Sen, David S Hong, Aung Naing, Cynthia E Herzog, Siqing Fu, Sarina A Piha-Paul, Jordi Rodon, Timothy ...> ;Clinical Cancer Research. 2023 May 1
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Blessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina Piha-Paul, Julia Ann Moore, Bulent Yilmaz, Deby Ogbonna, Daniel D Karp, Ecaterina Dumb...> ;Cancer. 2023 Jul 15
3 citations
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.
Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, David S Hong, Shumei Kato, Aung Naing, Sarina Piha-Paul, Siqing Fu, Apostolia Tsimberidou, Maria Cabanillas, Naifa...> ;NPJ Precision Oncology. 2023 Feb 18
14 citations
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
James J Harding, Sarina A Piha-Paul, Ronak H Shah, Jessica J Murphy, James M Cleary, Geoffrey I Shapiro, David I Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Shere...> ;Nature Communications. 2023 Feb 6
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer.
Son, J., Lin, H., Fu, S., Biter, A., Dumbrava, E., Karp, D., Naing, A., Pant, S., Piha-Paul, S., Rodon, J., Subbiah, V., Tsimberidou, A., Yap, T., Frumovitz, M., Jazae...> ;Journal of Immunotherapy and Precision Oncology. 2023 Feb 1
4 citations
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102).
Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, David S Hong, Aung Naing, Siqing Fu, Sarina Piha-Paul, Timothy A Yap, Daniel Karp, Jordi Rodon, Andy Livings...> ;Clinical Cancer Research. 2023 Jan 17
74 citations
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.
Timothy A Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric-Bernstam, Hagop M Kantarjian, Farhad Ravandi, Meghan E Collins, Maria ...> ;Nature Medicine. 2023 Jan 1
3 citations
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expans...
Shannon N Westin, Siqing Fu, Apostolia Tsimberidou, Sarina Piha-Paul, Fechukwu Akhmedzhanov, Bulent Yilmaz, Lacey McQuinn, Amanda L Brink, Jing Gong, Cheuk Hong Leung,...> ;Gynecologic Oncology. 2023 Jan 1
3 citations
A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous N...
Sarina Piha-Paul, George Simon, Chandra P Belani, Heman Chao, Kim Gaspar, Brenda Lee, Afshin Dowlati> ;JTO Clinical and Research Reports. 2022 Nov 1
5 citations
Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development.
Neeltje Steeghs, Aaron R Hansen, Glenn J Hanna, Elena Garralda, Haeseong Park, James Strauss, Michael Adam, Gossett Campbell, Jennifer Carver, Rachael Easton, Katherin...> ;Clinical and Translational Science. 2022 Nov 1
6 citations
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology.
Henry Hiep Vo, Siqing Fu, David S Hong, Daniel D Karp, Sarina Piha-Paul, Vivek Subbiah, Filip Janku, Aung Naing, Timothy A Yap, Jordi Rodon, Jaffer A Ajani, Carrie Car...> ;NPJ Precision Oncology. 2022 Oct 27
9 citations
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study.
Vinod Ravi, Aparna Subramaniam, Jing Zheng, Behrang Amini, Van A Trinh, Jocelyn Joseph, Robert G Mennel, Andrew J Bishop, Erich M Sturgis, Ryan P Goepfert, Sudha Yalam...> ;Cancer. 2022 Sep 15
Join now to see all

Lectures

A phase I, first-in-human, dose-escalation and dose-expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
2019 ASCO Annual Meeting - 6/1/2019
A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/re...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplifi...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

Signature Trial Program Aims for Rapid Delivery of Novel TherapiesAugust 4th, 2016
Novel Targeted Therapies May Benefit Patients with Metastatic Hormone Receptor–Positive/HER2-Negative Breast CancerDecember 9th, 2023
SABCS: Studies Suggest Novel Targeted Therapies May Benefit Patients with Metastatic HR+/ HER2- Breast CancerDecember 8th, 2023